Pathology Asia

Based in Singapore, Pathology Asia specializes in comprehensive clinical diagnostic services, enhancing healthcare quality across Southeast Asia and Australasia through advanced laboratory testing and diagnostic solutions. Pathology Asia Holdings Pte. Ltd. was founded in 2018 and operates as a significant player in clinical diagnostics.

The firm was acquired by TPG in July 2018 for USD 207 mn from Healthscope Ltd. The company provides diagnostic services across key markets, including Singapore and Australia, under the leadership of CEO Warren Mah. Pathology Asia is a leading provider of clinical diagnostic services across Southeast Asia and Australasia. It offers a wide range of solutions, including laboratory testing, phlebotomy services, on-site screening, and specimen transport.

The company operates advanced laboratories in Singapore, Malaysia, Vietnam, the Philippines, Indonesia, and Australia, serving hospitals, clinics, and healthcare providers who depend on accurate diagnostic data for patient care. In 2023, Pathology Asia reported a revenue of USD 154. 95 mn with an EBITDA of USD 41. 61 mn.

The company generates revenue through B2B contracts with healthcare facilities, leveraging its extensive test offerings and advanced laboratory capabilities. Pathology Asia plans to utilize its recent funding from TPG to enhance its service offerings and expand into new markets in the Asia-Pacific region. Following its acquisition in July 2018, the company aims to develop new diagnostic products and strengthen its digital healthcare platform. Specific geographical targets for expansion include further penetration into the markets of Vietnam and Indonesia by 2025.